240 related articles for article (PubMed ID: 36732631)
1. Nuclear condensates of YAP fusion proteins alter transcription to drive ependymoma tumourigenesis.
Hu X; Wu X; Berry K; Zhao C; Xin D; Ogurek S; Liu X; Zhang L; Luo Z; Sakabe M; Trubicka J; Łastowska M; Szulzewsky F; Holland EC; Lee L; Hu M; Xin M; Lu QR
Nat Cell Biol; 2023 Feb; 25(2):323-336. PubMed ID: 36732631
[TBL] [Abstract][Full Text] [Related]
2. YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis.
Pajtler KW; Wei Y; Okonechnikov K; Silva PBG; Vouri M; Zhang L; Brabetz S; Sieber L; Gulley M; Mauermann M; Wedig T; Mack N; Imamura Kawasawa Y; Sharma T; Zuckermann M; Andreiuolo F; Holland E; Maass K; Körkel-Qu H; Liu HK; Sahm F; Capper D; Bunt J; Richards LJ; Jones DTW; Korshunov A; Chavez L; Lichter P; Hoshino M; Pfister SM; Kool M; Li W; Kawauchi D
Nat Commun; 2019 Sep; 10(1):3914. PubMed ID: 31477715
[TBL] [Abstract][Full Text] [Related]
3. YAP1/TAZ drives ependymoma-like tumour formation in mice.
Eder N; Roncaroli F; Domart MC; Horswell S; Andreiuolo F; Flynn HR; Lopes AT; Claxton S; Kilday JP; Collinson L; Mao JH; Pietsch T; Thompson B; Snijders AP; Ultanir SK
Nat Commun; 2020 May; 11(1):2380. PubMed ID: 32404936
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis.
Szulzewsky F; Arora S; Hoellerbauer P; King C; Nathan E; Chan M; Cimino PJ; Ozawa T; Kawauchi D; Pajtler KW; Gilbertson RJ; Paddison PJ; Vasioukhin V; Gujral TS; Holland EC
Genes Dev; 2020 Aug; 34(15-16):1051-1064. PubMed ID: 32675324
[TBL] [Abstract][Full Text] [Related]
5. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.
Parker M; Mohankumar KM; Punchihewa C; Weinlich R; Dalton JD; Li Y; Lee R; Tatevossian RG; Phoenix TN; Thiruvenkatam R; White E; Tang B; Orisme W; Gupta K; Rusch M; Chen X; Li Y; Nagahawhatte P; Hedlund E; Finkelstein D; Wu G; Shurtleff S; Easton J; Boggs K; Yergeau D; Vadodaria B; Mulder HL; Becksfort J; Gupta P; Huether R; Ma J; Song G; Gajjar A; Merchant T; Boop F; Smith AA; Ding L; Lu C; Ochoa K; Zhao D; Fulton RS; Fulton LL; Mardis ER; Wilson RK; Downing JR; Green DR; Zhang J; Ellison DW; Gilbertson RJ
Nature; 2014 Feb; 506(7489):451-5. PubMed ID: 24553141
[TBL] [Abstract][Full Text] [Related]
6. Phase separation of YAP reorganizes genome topology for long-term YAP target gene expression.
Cai D; Feliciano D; Dong P; Flores E; Gruebele M; Porat-Shliom N; Sukenik S; Liu Z; Lippincott-Schwartz J
Nat Cell Biol; 2019 Dec; 21(12):1578-1589. PubMed ID: 31792379
[TBL] [Abstract][Full Text] [Related]
7. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
8. Supratentorial ependymoma in childhood: more than just RELA or YAP.
Zschernack V; Jünger ST; Mynarek M; Rutkowski S; Garre ML; Ebinger M; Neu M; Faber J; Erdlenbruch B; Claviez A; Bielack S; Brozou T; Frühwald MC; Dörner E; Dreschmann V; Stock A; Solymosi L; Hench J; Frank S; Vokuhl C; Waha A; Andreiuolo F; Pietsch T
Acta Neuropathol; 2021 Mar; 141(3):455-466. PubMed ID: 33481105
[TBL] [Abstract][Full Text] [Related]
9. Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features.
Andreiuolo F; Varlet P; Tauziède-Espariat A; Jünger ST; Dörner E; Dreschmann V; Kuchelmeister K; Waha A; Haberler C; Slavc I; Corbacioglu S; Riemenschneider MJ; Leipold A; Rüdiger T; Körholz D; Acker T; Russo A; Faber J; Sommer C; Armbrust S; Rose M; Erdlenbruch B; Hans VH; Bernbeck B; Schneider D; Lorenzen J; Ebinger M; Handgretinger R; Neumann M; van Buiren M; Prinz M; Roganovic J; Jakovcevic A; Park SH; Grill J; Puget S; Messing-Jünger M; Reinhard H; Bergmann M; Hattingen E; Pietsch T
Brain Pathol; 2019 Mar; 29(2):205-216. PubMed ID: 30246434
[TBL] [Abstract][Full Text] [Related]
10. MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis.
Kim J; Kwon H; Shin YK; Song G; Lee T; Kim Y; Jeong W; Lee U; Zhang X; Nam G; Jeung HC; Kim W; Jho EH
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13529-13540. PubMed ID: 32482852
[TBL] [Abstract][Full Text] [Related]
11. TEAD mediates YAP-dependent gene induction and growth control.
Zhao B; Ye X; Yu J; Li L; Li W; Li S; Yu J; Lin JD; Wang CY; Chinnaiyan AM; Lai ZC; Guan KL
Genes Dev; 2008 Jul; 22(14):1962-71. PubMed ID: 18579750
[TBL] [Abstract][Full Text] [Related]
12. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes.
Takadera M; Satomi K; Szulzewsky F; Cimino PJ; Holland EC; Yamamoto T; Ichimura K; Ozawa T
Acta Neuropathol Commun; 2020 Nov; 8(1):203. PubMed ID: 33228790
[TBL] [Abstract][Full Text] [Related]
14. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein.
Zhao B; Kim J; Ye X; Lai ZC; Guan KL
Cancer Res; 2009 Feb; 69(3):1089-98. PubMed ID: 19141641
[TBL] [Abstract][Full Text] [Related]
15. YAP-Mediated Recruitment of YY1 and EZH2 Represses Transcription of Key Cell-Cycle Regulators.
Hoxha S; Shepard A; Troutman S; Diao H; Doherty JR; Janiszewska M; Witwicki RM; Pipkin ME; Ja WW; Kareta MS; Kissil JL
Cancer Res; 2020 Jun; 80(12):2512-2522. PubMed ID: 32409309
[TBL] [Abstract][Full Text] [Related]
16. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.
Wang J; Wang H; Zhang Y; Zhen N; Zhang L; Qiao Y; Weng W; Liu X; Ma L; Xiao W; Yu W; Chu Q; Pan Q; Sun F
Cell Signal; 2014 May; 26(5):1048-59. PubMed ID: 24468535
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
18. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL
Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140
[TBL] [Abstract][Full Text] [Related]
19. IQGAP1 Binds to Yes-associated Protein (YAP) and Modulates Its Transcriptional Activity.
Sayedyahossein S; Li Z; Hedman AC; Morgan CJ; Sacks DB
J Biol Chem; 2016 Sep; 291(37):19261-73. PubMed ID: 27440047
[TBL] [Abstract][Full Text] [Related]
20. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
